New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance-Reference-Cited by-同舟云学术

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine–mitoxantrone–cyclophosphamide–alemtuzumab induction followed by alemtuzumab maintenance

Published:2018-09-20 Issue:3 Volume:60 Page:649-657
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Pflug Natali¹,Cramer Paula¹,Robrecht Sandra¹,Bahlo Jasmin¹,Westermann Anne¹,Fink Anna-Maria¹,Schrader Alexandra¹,Mayer Petra¹,Oberbeck Sebastian¹,Seiler Till²,Zenz Thorsten³,Dürig Jan⁴,Kreuzer Karl-Anton¹,Stilgenbauer Stephan⁵,Eichhorst Barbara¹,Hallek Michael¹,Herling Marco¹,Hopfinger Georg⁶

Affiliation:

1. Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, Deutsche CLL Studiengruppe (DCLLSG), Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), and Center of Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany;

2. Medizinische Klinik und Poliklinik III, LMU University of Munich, Munich, Germany;

3. National Center for Tumor Diseases Heidelberg, Heidelberg, Germany;

4. Klinik für Hämatologie, University of Essen, Essen, Germany;

5. Department of Internal Medicine III, University of Ulm, Ulm, Germany;

6. AKH Wien, Universitätsklinik für Innere Medizin I, Vienna, Austria

Funder

University of Cologne

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link